Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is expected to report a net loss of between 83 million to 99 million yuan for the year 2025, marking its first annual loss since going public, with a year-on-year decline of 217.63% to 198.62% [2][3] Financial Performance - In 2024, the company experienced a slight decline in revenue, achieving 2.16 billion yuan, a decrease of 0.63% year-on-year; net profit attributable to shareholders fell by 37.66% to 84.16 million yuan, while the net profit after deducting non-recurring items dropped by 56.89% to 49.87 million yuan [3] - The projected net loss for 2025 represents a decrease of 166.7 million to 183 million yuan compared to the previous year, with a decline exceeding 200%; the net profit after deducting non-recurring items is expected to be a loss of 32.5 million to 39 million yuan, down by 82.37 million to 88.87 million yuan [3] Regulatory Impact - The company faced a significant antitrust fine of 61.04 million yuan, which directly impacted its net profit; this fine accounted for 72.53% of the audited net profit for 2024 and 2.83% of the annual revenue, leading to a direct reduction of 61.04 million yuan in the projected net profit for 2025 [4] Operational Challenges - The company is under pressure from industry policy adjustments, high R&D costs, and restricted financing channels, which have contributed to its declining performance; the core product's gross margin is under pressure due to national drug procurement policies and increased international market competition [5] - The price of dexamethasone phosphate sodium, a key raw material, has plummeted to between 0.23 yuan and 0.57 yuan per unit post-antitrust penalty, significantly lower than the maximum price of 98.76 yuan during the period of monopoly, compressing the profitability of related businesses [5] R&D and Financing - The company has been increasing its R&D investment significantly, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, averaging over 30% annual growth; however, this sustained investment continues to pressure profit margins [5] - The company has faced challenges in financing, with two failed fundraising attempts in 2024 totaling 7.35 million yuan, which were terminated due to "market environment changes and the company's actual operating conditions"; it has since sought debt financing, applying for a 240 million yuan R&D loan [6] Future Outlook - The company is exploring how to address the profit gap created by the antitrust fine and whether the 240 million yuan R&D loan will be successfully secured; there are concerns regarding its cash flow situation and how it will restructure its core profit segments to achieve profitability [7]

Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient Dexamethasone Sodium Phosphate [1] Group 1: Company Developments - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, has been granted a CEP certificate for Dexamethasone Sodium Phosphate, indicating compliance with European pharmacopoeia standards [1] - Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties [1] Group 2: Product Applications - The drug is primarily used for treating allergic and autoimmune inflammatory diseases, including connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, and acute leukemia [1] - It is also utilized in the comprehensive treatment of certain severe infections, poisoning, and malignant lymphomas [1]

Core Viewpoint - Saito Bio's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received the CEP certificate for Dexamethasone Sodium Phosphate from the European Directorate for the Quality of Medicines (EDQM), enhancing its position in the pharmaceutical market [1] Company Summary - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, applied for the CEP certificate for Dexamethasone Sodium Phosphate in April 2024 and received it in October 2025 [1] - The drug Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties, primarily used for allergic and autoimmune inflammatory diseases [1] Industry Summary - There are a total of 9 companies globally that hold valid CEP certificates for Dexamethasone Sodium Phosphate, including Shandong Sry Pharmaceutical [1]

Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Core Viewpoint - The antitrust case involving dexamethasone raw material has concluded, resulting in significant fines for Jiangsu Lianhuan Pharmaceutical Co., Ltd. and its competitors, impacting their financial performance and future operations [1][2][4]. Group 1: Regulatory Actions and Financial Impact - Jiangsu Lianhuan Pharmaceutical was fined a total of 61.0382 million yuan, which represents 72.53% of its net profit for the previous year [3][4]. - The total fines imposed on the three companies involved in the price-fixing agreement amount to 326 million yuan [4]. - The fines include the confiscation of illegal gains of 17.8992 million yuan and an 8% penalty based on the company's 2023 sales [2][4]. Group 2: Financial Performance and R&D Investment - In 2024, Jiangsu Lianhuan reported a revenue of 2.16 billion yuan, a slight decrease of 0.63% year-on-year, and a net profit of 84.16 million yuan, down 37.66% from the previous year [6]. - The company has significantly increased its R&D investment, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, reflecting a compound annual growth rate of over 51% [7][8]. - The increase in R&D spending has pressured profit margins, leading to a decline in net profit despite revenue growth [7][8]. Group 3: Market Position and Competitive Landscape - Dexamethasone phosphate sodium is included in the treatment guidelines for severe COVID-19 patients, highlighting its importance in the pharmaceutical market [3]. - The company is shifting focus towards high-end formulations and innovative drugs, including projects targeting cancer and Alzheimer's disease [7][8]. - The innovative drug LH-1801, currently in phase III clinical trials, faces competition from several similar products already on the market [9].

Product Line and Applications - The company's intermediate product line includes five main series: Androstenedione (AD), Androstenedione (ADD), 9-Hydroxyandrostenedione (9OH-AD), 17α-hydroxy derivatives (A ring), and Dihydrotestosterone (BA), primarily used in the production of steroid drugs for various medical applications [1][2]. Quality Control and Management - The company adheres to strict quality management systems across all production stages, implementing international GMP standards to ensure product quality stability and consistency [2][3]. - In 2024, the company reported a net cash flow from operating activities of approximately ¥194.46 million, a 309.44% increase from the previous year, attributed to reduced cash payments for purchased goods and increased receipts from sales [4]. Research and Development - R&D investments have steadily increased from ¥50.21 million in 2022 to ¥58.38 million in 2024, supporting the company's industrial upgrades and performance growth [4][5]. - The company has accumulated nearly ¥400 million in R&D investments, with over 90 patents, including 25 invention patents, enhancing its competitive edge in the market [6]. Environmental and Sustainability Initiatives - The company is recognized as a national-level green factory, utilizing synthetic biology and genetic engineering technologies to improve environmental sustainability in production processes [3][5]. - Various energy-saving measures have been implemented to reduce carbon emissions, including advanced technology adoption to lower material consumption and pollution [5]. Market Position and Strategy - The global steroid hormone drug market is growing at over 10% annually, with the company positioned to capitalize on this trend, as China's steroid hormone raw material production accounts for about one-third of the global total [7][9]. - The company aims to integrate its operations across the pharmaceutical value chain, focusing on the production of intermediates, raw materials, and finished formulations [10][11]. Employee and Labor Relations - The company emphasizes employee rights protection, adhering to labor laws and establishing a comprehensive human resource management system to foster a harmonious labor relationship [11]. Future Outlook - The company plans to expand its international market presence, with overseas revenue accounting for 18.55% of total revenue in 2024, and aims to register multiple raw materials in the US and EU to facilitate exports [11].